Curious to keep this conversation going as SOC was the very thing that the crew was talking about in terms of informing trial design for the adult sR-aGvHD.
One thing I took away from the conference call that Tanushree Jain (BP Analyst) asked was on precisely that - whether they would be opting for a superiority trial or a non-inferiority trial, where the SOC would be used as the comparator.
Some light weekend reading assigned by Mr James:
Comparisons of Superiority, Non-inferiority, and Equivalence Trials
Comparisons of Superiority, Non-inferiority, and Equivalence Trials
In the literature-
"There is no accepted standard-of-care treatment for SR-aGVHD [11, 34]. This is due to most studies in SR-aGVHD being retrospective, single-arm, phase 2 studies [8, 11, 35], which cannot be easily compared with current patient populations due to significant changes in not only supportive care but also prophylaxis of GVHD. In addition, there are a lack of standardized endpoints, small numbers of enrolled patients, and decreased survival rates, making it difficult to compare data across studies [6, 8]." [source: here]
If you read between the lines, should the Prof and his crew pursue a superiority trial against the current SOC for adult sR-aGvHD (which they are already deep in planning with the top minds in oncology as mentioned both last night and this morning), one might end up in a situation where ruxo might be booted out as rem-L steps up to the plate out-performing on all fronts. If I was an INCY holder, I'd be quaking right about now if the company hasn't made any plans to refine the DP that's currently being used after the patients become steroid-refractory (the stats are that 35-50% of patients end up like that (source: here).
If there's a ruxo V2.0, I'd love to see it.
@nosluggos, you mentioned - "Whether the difference be significant enough to justify stopping the trial (ie and approving for use) on Covid ARDS patients at the 30% or 45% readouts?"
I wonder what the null hypothesis for the trial... that would be something that would point us to the primary endpoint no?
Thoughts anyone?
- Forums
- ASX - By Stock
- MSB
- MSB Trading 2020 - a new dawn
MSB
mesoblast limited
Add to My Watchlist
2.48%
!
$1.58

MSB Trading 2020 - a new dawn, page-540
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.58 |
Change
-0.040(2.48%) |
Mkt cap ! $2.063B |
Open | High | Low | Value | Volume |
$1.61 | $1.61 | $1.57 | $1.387M | 875.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 59292 | $1.58 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.58 | 8511 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 37760 | 1.575 |
10 | 124510 | 1.570 |
12 | 175110 | 1.565 |
20 | 165855 | 1.560 |
12 | 90773 | 1.555 |
Price($) | Vol. | No. |
---|---|---|
1.580 | 19964 | 2 |
1.585 | 65321 | 5 |
1.590 | 33028 | 3 |
1.595 | 37394 | 5 |
1.600 | 29889 | 6 |
Last trade - 10.11am 08/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
AGC
AUSTRALIAN GOLD AND COPPER LTD
Glen Diemar, MD
Glen Diemar
MD
SPONSORED BY The Market Online